Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* PURA VIDA INVESTMENTS, LLC	2. Issuer Name and Ticker or Trading Symbol Oncocyte Corp [ OCX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 512 W 22ND STREET, 7TH FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 4/14/2022
(Street) NEW YORK, NY 10011 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 4/18/2022	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	4/14/2022		P		1665898 ⁽¹⁾	A	$1.3325	7350447	I	By Pura Vida Master Fund, Ltd. ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		30790	A	$1.2270	7381237	I	By Pura Vida Master Fund, Ltd. ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		92370	A	$1.2600	7473607	I	By Pura Vida Master Fund, Ltd. ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		1916419 ⁽¹⁾	A	$1.3325	8455823	I	By the Managed Accounts ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		19210	A	$1.2270	8475033	I	By the Managed Accounts ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		57630	A	$1.2600	8532663	I	By the Managed Accounts ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		767952 ⁽¹⁾	A	$1.3325	767952	I	By Pura Vida X Fund LP ⁽²⁾⁽³⁾
Common Stock	4/14/2022		P		1381438 ⁽¹⁾	A	$1.3325	1381438	I	By the Retirement Trust ⁽²⁾⁽³⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant to purchase common stock	$1.53	4/14/2022		P		832949		4/19/2022 ⁽⁴⁾	4/19/2027	Common Stock	832949	⁽¹⁾	832949	I	By Pura Vida Master Fund, Ltd. ⁽²⁾⁽³⁾
Warrant to purchase common stock	$1.53	4/14/2022		P		383976		4/19/2022 ⁽⁴⁾	4/19/2027	Common Stock	383976	⁽¹⁾	383976	I	By Pura Vida X Fund LP ⁽²⁾⁽³⁾
Warrant to purchase common stock	$1.53	4/14/2022		P		690719		4/19/2022 ⁽⁴⁾	4/19/2027	Common Stock	690719	⁽¹⁾	690719	I	By the Retirement Trust ⁽²⁾⁽³⁾
Warrant to purchase common stock	$1.53	4/14/2022		P		958209		4/19/2022 ⁽⁴⁾	4/19/2027	Common Stock	958209	⁽¹⁾	958209	I	By the Managed Accounts ⁽²⁾⁽³⁾

Explanation of Responses:
(1)	Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325.
(2)	Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
(3)	By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.
(4)	The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise.

Remarks:
This amendment to the Form 4 is being filed solely to correct the address reported for Efrem Kamen.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET 7TH FLOOR NEW YORK, NY 10011		X
Kamen Efrem C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET 7TH FLOOR NEW YORK, NY 10011		X

Signatures
/s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC		4/29/2022
^**Signature of Reporting Person		Date
/s/ Efrem Kamen		4/29/2022
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

OncoCyte (AMEX:OCX)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023

Plus de graphiques de la Bourse OncoCyte

OncoCyte (AMEX:OCX)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023

OCX

Actualités Oncocyte Corp